Qube Research & Technologies LTD Cytom X Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 55,108 shares of CTMX stock, worth $42,984. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,108
Previous 55,108
-0.0%
Holding current value
$42,984
Previous $65,000
13.85%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CTMX
# of Institutions
71Shares Held
46.1MCall Options Held
3.7KPut Options Held
4.7K-
Tang Capital Management LLC San Diego, CA7.31MShares$5.7 Million0.57% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.08 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$4.03 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX3.91MShares$3.05 Million1.19% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.22MShares$2.51 Million0.0% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $51.4M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...